| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6252 | 2012 |
| Screening for epidermal growth factor receptor mutations in lung cancer R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ... New England Journal of Medicine 361 (10), 958-967, 2009 | 2938 | 2009 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 623 | 2018 |
| Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ... The Lancet Oncology 20 (8), 1124-1135, 2019 | 410 | 2019 |
| Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ... The Lancet Oncology 21 (2), 261-270, 2020 | 404 | 2020 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 338 | 2021 |
| KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target M Román, I Baraibar, I López, E Nadal, C Rolfo, S Vicent, I Gil-Bazo Molecular cancer 17, 1-14, 2018 | 333 | 2018 |
| Impact of the COVID-19 pandemic on cancer care: a global collaborative study AR Jazieh, H Akbulut, G Curigliano, A Rogado, AA Alsharm, ED Razis, ... JCO global oncology 6, 1428-1438, 2020 | 254 | 2020 |
| The role of nuclear factor-kappa B signaling in human cervical cancer S Tilborghs, J Corthouts, Y Verhoeven, D Arias, C Rolfo, XB Trinh, ... Critical reviews in oncology/hematology 120, 141-150, 2017 | 251 | 2017 |
| FGFR a promising druggable target in cancer: Molecular biology and new drugs R Porta, R Borea, A Coelho, S Khan, A Araújo, P Reclusa, T Franchina, ... Critical reviews in oncology/hematology 113, 256-267, 2017 | 241 | 2017 |
| A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma L Sorber, K Zwaenepoel, V Deschoolmeester, G Roeyen, F Lardon, ... The journal of molecular diagnostics 19 (1), 162-168, 2017 | 229 | 2017 |
| Liquid biopsies in lung cancer: the new ambrosia of researchers C Rolfo, M Castiglia, D Hong, R Alessandro, I Mertens, G Baggerman, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 539-546, 2014 | 221 | 2014 |
| Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies N Boeckx, R Koukakis, KO De Beeck, C Rolfo, G Van Camp, S Siena, ... Annals of Oncology 28 (8), 1862-1868, 2017 | 214 | 2017 |
| RET fusions in solid tumors AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, ... Cancer treatment reviews 81, 101911, 2019 | 187 | 2019 |
| CD70: An emerging target in cancer immunotherapy J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, ... Pharmacology & therapeutics 155, 1-10, 2015 | 186 | 2015 |
| Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer U Malapelle, R Sirera, E Jantus-Lewintre, P Reclusa, S Calabuig-Fariñas, ... Expert review of molecular diagnostics 17 (3), 209-215, 2017 | 176 | 2017 |
| Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients L Sorber, K Zwaenepoel, V Deschoolmeester, PEY Van Schil, ... Lung cancer 107, 100-107, 2017 | 175 | 2017 |
| Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ... Drug Resistance Updates 46, 100644, 2019 | 169 | 2019 |
| PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016 | 169 | 2016 |
| Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges VSS Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C ... Nat Rev Clin Oncol, 2017 | 165 | 2017 |
Alessandro RussoMedical Oncology Unit AO Papardo & Department of Human Pathology, University of MessinaVerified email at studenti.unime.it
